Company

BioMap

百图生科

BioMap (百图生科) is a Beijing-based biotech platform founded in 2020 by Baidu founder Robin Li and BlueRun Ventures partner Liu Wei, per a 2022 BlueRun Ventures piece . The company bills itself as China's first bio-computing engine for innovative drug discovery, built around a multi-trillion-parameter AI foundation model called "xTrimo" that spans proteins, immune cells, and immune-system modeling .

Its signature product is the "ImmuBot" (免疫机器人), a programmable immunotherapy platform designed to reprogram the immune system for dozens of immune-related diseases . By 2022, BioMap had established R&D centers in Beijing, Suzhou, and Silicon Valley, plus high-throughput wet labs, and had launched over 30 proprietary drug programs targeting oncology and autoimmune conditions .

The company has pursued a distinctly model-centric commercial strategy. In October 2023, it announced a partnership with Sanofi valued at over $1 billion in total potential payments, structured around model-development milestones rather than traditional drug-development progress — what BlueRun described as a "Model as a Service" approach for life sciences . In mid-2024, BioMap opened its first international innovation hub in Hong Kong, backed by a strategic agreement with Hong Kong Investment Management Corporation Limited, with plans to support 50+ early-stage bio-computing projects over five years through its "BioMap BioX" accelerator . BlueRun Ventures, an early investor, has featured BioMap repeatedly in its portfolio communications .

AI-generated — may contain errors, please verify.

BioMapCompany
百图生科
渲染中…
Mentioned in 245 articles

Coverage